Institutional & Family Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Institutional & Family Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-94	Closed	-$8K	–	780
2021 Q4	$8K	Hold	94	–	–	﹤0.01%	470
2021 Q3	$7K	Hold	94	–	–	﹤0.01%	602
2021 Q2	$8K	Hold	94	–	–	﹤0.01%	627
2021 Q1	$7K	Sell	94 -115	-55%	-$9.39K	﹤0.01%	613
2020 Q4	$18K	Hold	209	–	–	﹤0.01%	451
2020 Q3	$16K	Hold	209	–	–	﹤0.01%	423
2020 Q2	$26K	Sell	209 -8	-4%	-$795	0.01%	373
2020 Q1	$18K	Sell	217 -2	-0.9%	-$172	﹤0.01%	380
2019 Q4	$19K	Hold	219	–	–	﹤0.01%	436
2019 Q3	$15K	Buy	219 +3	+1%	+$231	﹤0.01%	427
2019 Q2	$19K	Buy	216 +59	+38%	+$5.05K	﹤0.01%	425
2019 Q1	$14K	Hold	157	–	–	﹤0.01%	457
2018 Q4	$13K	Buy	157 +10	+7%	+$951	﹤0.01%	436
2018 Q3	$14K	Buy	147 +13	+10%	+$1.3K	﹤0.01%	477
2018 Q2	$13K	Buy	+134	New	+$11.7K	﹤0.01%	481

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Institutional & Family Asset Management's BMRN Position: Q1 2022 in Review

Institutional & Family Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2022, closing a stake of 94 shares — an estimated $8K sold.

Institutional & Family Asset Management first reported a position in BMRN in Q2 2018 and held it in 15 quarters. The position peaked at $26K in Q2 2020. 561 funds tracked by Wall St. Rank hold BMRN as of Q1 2022.

Institutional & Family Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Institutional & Family Asset Management sold 94 BioMarin Pharmaceuticals shares in Q1 2022, an estimated $8K.
Institutional & Family Asset Management first reported a position in BioMarin Pharmaceuticals in Q2 2018 and held it in 15 quarters.
Institutional & Family Asset Management's BioMarin Pharmaceuticals position peaked at $26K in Q2 2020.
561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2022.

Based on Institutional & Family Asset Management's 13F filing for Q1 2022, filed 11 May 2022.